Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity,  current microbial and mammalian capabilities, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones.

View the video below to hear from Stijn Cattaert, Director of Business Development, on the agility and experience that make Team Cytovance the ideal CDMO partner for your H2 2025 programs.